Progress in diagnosis and treatment of hyperuricemia in children with tumor lysis syndrome

doi:10.3969/j.issn.1006-7795.2019.03.030

Journal of Capital Medical University ›› 2019, Vol. 40 ›› Issue (3): 483-487.doi: 10.3969/j.issn.1006-7795.2019.03.030

Previous Articles Next Articles

Progress in diagnosis and treatment of hyperuricemia in children with tumor lysis syndrome

Jiang Li, Zheng Huyong

Beijing Key Laboratory of Pediatric Hematology Oncology;National Key Discipline of Pediatrics(Capital Medical University);Key Laboratory of Major Diseases in Children, Ministry of Education;Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

Received:2018-12-06 Online:2019-05-21 Published:2019-06-13
Supported by:
This study was supported by Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Grant (ZY201404),Beijing Municipal Administration of Hospitals Deng Feng Program (DFL20151101),Capital Health and Development of Special Grant (2016-1-2091)

Abstract

Abstract: Hyperuricemia is a serious complication of tumor lysis syndrome (TLS). Uric acid is the end product of purine in the human body. Almost all of the uric acid in the blood is filtered by the glomeruli, and the accumulation of uric acid caused by TLS exceeds the capacity of glomeruli, which results in "hyperuricemia". Excessive uric acid reaches tissues and organs with blood and causes systemic disease. Patients may have symptoms such as nausea, vomiting, joint pain and renal colic. If hyperuricemia causes acute urate nephropathy, severe azotemia and renal failure will occur. In the past, only allopurinol was available for pediatricians to prevent hyperuricemia, while there was no specific drug for the established hyperuricemia. In the last 16 years, Due to the use of uric acid oxidase, pediatricians have become more proficient in the prevention and treatment of hyperuricemia caused by TLS. This review focuses on the hyperuricemia and clinical application of uric acid oxidase.

Key words: tumor lysis syndrome, hyperuricemia, uric acid oxidase

CLC Number:

R725.5

Jiang Li, Zheng Huyong. Progress in diagnosis and treatment of hyperuricemia in children with tumor lysis syndrome[J]. Journal of Capital Medical University, 2019, 40(3): 483-487.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.03.030

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I3/483

References

[1] Ward E, Desantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014[J]. CA Cancer J Clin,2014,64(2):83-103.
[2] Coiffier B, Altman A, Pui C H, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome:an evidence-based review[J]. J Clin Oncol,2008,26(16):2767-2778.
[3] Noone D G, Marks S D. Hyperuricemia is associated with hypertension, obesity, and albuminuria in children with chronic kidney disease[J]. J Pediatr,2013,162(1):128-132.
[4] Cairo M S, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases:an expert TLS panel consensus[J]. Br J Haematol,2010,149(4):578-586.
[5] Ejaz A A, Pourafshar N, Mohandas R, et al. Uric acid and the prediction models of tumor lysis syndrome in AML[J]. PLoS One,2015,10(3):e119497.
[6] Strauss P Z, Hamlin S K, Dang J. Tumor lysis syndrome:a unique solute disturbance[J]. Nurs Clin North Am,2017,52(2):309-320.
[7] Abu-Alfa A K, Younes A. Tumor lysis syndrome and acute kidney injury:evaluation, prevention, and management[J]. Am J Kidney Dis,2010,55(5 Suppl 3):S1-S13, quiz S14-S19.
[8] Kang D H, Park S K, Lee I K, et al. Uric acid-induced C-reactive protein expression:implication on cell proliferation and nitric oxide production of human vascular cells[J]. J Am Soc Nephrol,2005,16(12):3553-3562.
[9] Cirillo P, Gersch M S, Mu W, et al. Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells[J]. J Am Soc Nephrol,2009,20(3):545-553.
[10] Han H J, Lim M J, Lee Y J, et al. Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-kappaB[J]. Am J Physiol Renal Physiol,2007,292(1):F373-F381.
[11] Shimada M, Dass B, Ejaz A A. Paradigm shift in the role of uric acid in acute kidney injury[J]. Semin Nephrol,2011,31(5):453-458.
[12] Larosa C, Mcmullen L, Bakdash S, et al. Acute renal failure from xanthine nephropathy during management of acute leukemia[J]. Pediatr Nephrol,2007,22(1):132-135.
[13] Hochberg J, Cairo M S. Tumor lysis syndrome:current perspective[J]. Haematologica,2008,93(1):9-13.
[14] Patte C, Sakiroglu O, Sommelet D. European experience in the treatment of hyperuricemia[J]. Semin Hematol,2001,38(4 Suppl 10):9-12.
[15] Wilson F P, Berns J S. Tumor lysis syndrome:new challenges and recent advances[J]. Adv Chronic Kidney Dis,2014,21(1):18-26.
[16] Finkel K W, Howard S C. Renal disease in cancer patients[M].Massachusetts:Academic Press,2014:39-64.
[17] Goldman S C, Holcenberg J S, Finklestein J Z, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis[J]. Blood,2001,97(10):2998-3003.
[18] Cheuk D K, Chiang A K, Chan G C, et al. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer[J]. Cochrane Database Syst Rev,2017,3:CD006945.
[19] Cairo M S, Thompson S, Tangirala K, et al. A Clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome[J]. Clin Lymphoma Myeloma Leuk,2017,17(3):173-178.
[20] Kikuchi A, Kigasawa H, Tsurusawa M, et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome[J]. Int J Hematol,2009,90(4):492-500.
[21] Syrimi E, Gunasekera S, Norton A, et al. Single dose rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden[J]. Br J Haematol,2018,181(5):696-698.
[22] Yu X, Liu L, Nie X, et al. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults:a systematic review and meta-analysis[J]. J Clin Pharm Ther,2017,42(1):18-26.
[23] Criscuolo M, Fianchi L, Dragonetti G, et al. Tumor lysis syndrome:review of pathogenesis, risk factors and management of a medical emergency[J]. Expert Rev Hematol,2016,9(2):197-208.
[24] Eaddy M, Seal B, Tangirala M, et al. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients[J]. Am J Health Syst Pharm,2010,67(24):2110-2114.
[25] Pui C H, Relling M V, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies[J]. Leukemia,1997,11(11):1813-1816.
[26] Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Societe Francaise d'Oncologie Pediatrique LMB89 protocol[J]. Ann Oncol,2002,13(5):789-795.
[27] Wossmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase[J]. Ann Hematol,2003,82(3):160-165.
[28] Patel C, Wilson C P, Ahmed N, et al. Acute Uric acid nephropathy following epileptic seizures:case report and review[J]. Case Rep Nephrol,2019,2019:4890287.

Progress in diagnosis and treatment of hyperuricemia in children with tumor lysis syndrome

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments

[1]	Yang Zheng;Hua Qi;Xing Xiurong;Liu Rongkun . The Relationship between Blood Uric Acid and Lipid in Hypertensive Patients [J]. Journal of Capital Medical University, 2006, 27(3): 369-371.
[2]	Zhang Lijing;Hu Dayi;Yang Jingang;Xu Yuyun;Li Tianchang;Wang Guohong;Shi Xubo;Lu Yafeng . Prevalence of Hyperuricemia in Patients with Cardiovascular Risk Factors [J]. Journal of Capital Medical University, 2005, 26(2): 124-127.